SCHEMBL835940

SCHEMBL835940

C[C@H](NC(=O)O)C(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.54
CES2 O00748 2/20 0.51
CES1 P23141 2/20 0.51
SRD5A2 P31213 1/20 0.47
PTPN1 P18031 2/20 0.46
NR4A1 P22736 1/20 0.46
NR4A2 P43354 1/20 0.46
NR4A3 Q92570 1/20 0.46
TRPV1 Q8NER1 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
LMNA P02545 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER2 P43116 1/20 0.43
SLC6A4 P31645 1/20 0.43
MLYCD O95822 1/20 0.42
EPHX2 P34913 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22344680 0.83 CES2 (0.48) CES2NPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4534271 0.83 CES2 (0.48) CES2NPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL16857194 0.81 NPC1 (0.50) CES2CES1NPC1LMNACYP3A4
SCHEMBL1743898 0.80 PPARG (0.52) GSK3BCES2CES1TRPV1NPC1
SCHEMBL850968 0.80 PPARG (0.52) GSK3BCES2CES1TRPV1NPC1
SCHEMBL8383097 0.79 CA12 (0.45) CES2SRD5A2LMNACYP3A4
SCHEMBL9835782 0.79 CA12 (0.45) CES2SRD5A2LMNACYP3A4
SCHEMBL22344614 0.78 SLC6A3 (0.51) CES2CES1NPSR1CYP3A4CYP2C9
SCHEMBL1287117 0.78 PGR (0.47) CES2CES1NPC1RAB9ALMNA
SCHEMBL3495542 0.78 PGR (0.47) CES2CES1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252770-A1 Chemical Compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 US disclosed
EP-2102169-B1 INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS ASTRAZENECA AB (SE) 2012-06-20 EP disclosed
US-8143290-B2 Chemical compounds 572 ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20110071194-A1 Chemical Compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-24 US disclosed
US-20100197644-A1 Chemical Compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-08-05 US disclosed
US-7728030-B2 Chemical compounds 572 ASTRAZENECA AB (SE) 2010-06-01 US disclosed
US-20080214641-A1 Chemical compounds 572 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214641-A1 Chemical compounds 572 ABCG2, ABCB1, CYP11B2 GSK3B 2322/4885CES2 206/4885CES1 808/4885
US-20100197644-A1 Chemical Compounds 572 ABCG2, ABCB1, CYP11B2 GSK3B 2322/4885CES2 206/4885CES1 808/4885
US-20120252770-A1 Chemical Compounds 572 ABCG2, ABCB1, CYP11B2 GSK3B 2322/4885CES2 206/4885CES1 808/4885
US-20110071194-A1 Chemical Compounds 572 ABCG2, ABCB1, CYP11B2 GSK3B 2322/4885CES2 206/4885CES1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.